In the current study, we used a 27-gene panel assay to: (i) identify additional prognostically-relevant mutations in CMML, (ii) to determine if the number of mutations carries prognostic relevance and (iii) to study the prognostic interplay between TET2 and ASXL1 mutations. The gene discussed is TET2; the disease is chronic myelomonocytic leukemia.